Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04520321 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/ Phase 2 Study of TTHX1114(NM141)
A Phase 1 study of Endothelial Dysfunction and Fuchs Endothelial Corneal Dystrophy, sponsored by Trefoil Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
- 8
- Study locations
NCT04520321: Completed Phase 1 study of Endothelial Dysfunction and Fuchs Endothelial Corneal Dystrophy, sponsored by Trefoil Therapeutics.
NCT04520321 is a Phase 1 study of Endothelial Dysfunction and Fuchs Endothelial Corneal Dystrophy that has completed, run by Trefoil Therapeutics. The registered enrollment target is 22 participants, below the 92-participant average among 45 other Endothelial Dysfunction trials with a reported enrollment target (76% lower). The trial reports 8 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04520321, a Phase 1 study of Endothelial Dysfunction and Fuchs Endothelial Corneal Dystrophy, has completed, sponsored by Trefoil Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
- 8
- Study locations
Study Summary
Prospective, multicenter, randomized, masked, vehicle-controlled, dose-escalation study
Primary Outcome
Suspected Adverse Reactions Reported Following Study Drug Adminsitration
Conditions Studied
Interventions
- DRUG TTHX1114(NM141)
- OTHER Vehicle (placebo)
Study Locations (8)
California
- North Bay Eye Associates, Inc. - Petaluma
Florida
- Levenson Eye Associates, Inc - Jacksonville
Illinois
- Chicago Corneal Consultants - Hoffman Estates
Indiana
- Price Vision Group - Indianapolis
Missouri
- Tauber Eye Center - Kansas City
Nebraska
- Vance Thompson Vision - Omaha - Omaha
New York
- Alterman, Modi and Wolter - Poughkeepsie
South Dakota
- Vance Thompson Vision - Sioux Falls - Sioux Falls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2020-08-19 |
| Est. Completion | 2021-05-18 |
| Phase | Phase 1 |
What the finished NCT04520321 record still lists
NCT04520321 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 92-participant average among 45 other Endothelial Dysfunction trials with a reported enrollment target (76% lower).
The record links to 4 conditions, with Endothelial Dysfunction appearing as the primary indexed condition, and to 2 interventions - of which TTHX1114(NM141) is the first listed.
NCT04520321 lists 8 locations in 8 states (California, Florida, Illinois).
Frequently Asked Questions
What is clinical trial NCT04520321 about?
NCT04520321 is a clinical study titled "A Phase 1/ Phase 2 Study of TTHX1114(NM141)". Prospective, multicenter, randomized, masked, vehicle-controlled, dose-escalation study
What is the current status of trial NCT04520321?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2020-08-19. Estimated completion is 2021-05-18.
What conditions does trial NCT04520321 study?
This clinical trial studies the following conditions: Endothelial Dysfunction, Fuchs Endothelial Corneal Dystrophy, Pseudophakic Bullous Keratopathy, Corneal Endothelial Dystrophy.
What interventions are being tested in trial NCT04520321?
The interventions under investigation include: TTHX1114(NM141) (DRUG), Vehicle (placebo) (OTHER).
Who is sponsoring clinical trial NCT04520321?
This trial is sponsored by Trefoil Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04520321 being conducted?
This trial has 8 study locations across California, Florida, Illinois, Indiana, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endothelial Dysfunction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04520321's enrollment target sits among peer trials
22 40th of 45 higher than 6 of 45 other Endothelial Dysfunction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endothelial Dysfunction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes
RECRUITING · Phase 1
-
Effect of a Daily Supplement on Plasma PAI-1 Levels
RECRUITING · Phase 1
-
B-Complex: A Nutraceutical SANS Countermeasure
RECRUITING · Phase 1
-
Fisetin to Improve Vascular Function in Older Adults
ACTIVE NOT RECRUITING · Phase 1
-
Wild Blueberries and Cardiovascular Health in Middle-aged/Older Men and Postmenopausal Women
ACTIVE NOT RECRUITING · Phase 1
-
Enhancing Parasympathetic Activity to Improve Endothelial Dysfunction, Vascular Oxidative Stress in African Americans
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI